Individuals with pulmonary fibrosis could develop more serious complications if infected with COVID-19, and those awaiting organ transplantation and other surgical interventions may face delays because of the pandemic.
Researchers confirmed the feasibility of conducting a randomized, triple-blinded, sham-controlled trial of ambulatory oxygen delivered via portable oxygen concentrator to evaluate its effects in patients with interstitial lung disease.
There are significant differences in perceptions of prevalence, risk factors, and the management of RA-associated interstitial lung disease between rheumatologists and pulmonologists.
Lung ultrasound B-lines can depict modifications in the lung parenchyma of patients with systemic sclerosis and may be an independent predictor of additional pulmonary deterioration in individuals with the disease.
The FDA has approved Ofev (nintedanib; Boehringer Ingelheim) for the treatment of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
